Key points are not available for this paper at this time.
In patients with advanced or recurrent endometrial cancer, the addition of pembrolizumab to standard chemotherapy resulted in significantly longer progression-free survival than with chemotherapy alone. (Funded by the National Cancer Institute and others; NRG-GY018 ClinicalTrials.gov number, NCT03914612.).
Building similarity graph...
Analyzing shared references across papers
Loading...
Ramez N. Eskander
Michael W. Sill
Lindsey Beffa
New England Journal of Medicine
Johns Hopkins University
Cornell University
University of California, San Diego
Building similarity graph...
Analyzing shared references across papers
Loading...
Eskander et al. (Mon,) studied this question.
www.synapsesocial.com/papers/6941d148114bda084150ec9b — DOI: https://doi.org/10.1056/nejmoa2302312
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: